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1  | INTRODUCTION
Diabetes mellitus (DM) is a common chronic metabolic disorder char-
acterized by dysregulation of blood glucose and has been considered 
as a major global health issue now and in the future. DM presents in 
two main forms: Type 1 insulin-dependent DM (T1DM) constitute 
10% of all DM cases, and type 2 non-insulin-dependent DM (T2DM) 
constitute 90% of all DM cases. It is predicted that the number of 
patients with diabetes will increase from 350 million today to 592 
million by 2035 (Lee et al., 2016). Management of T2DM normally 
involves lifestyle modification and pharmacologic therapy. Several 
drugs, which are approved to treat hyperglycemia in T2DM, are 
costly and have serious side effects. For example, glucagon-like pep-
tide-1 (GLP-1) receptor agonists have been shown to increase the 
risk of kidney injury (Qaseem et al., 2017). The serious side effect 
and the toxicity associated with some therapeutic drugs indicate the 
demand for diet-derived antidiabetic agents or approaches that are 
considered natural and safe. Enzymes associated with the regulation 
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Abstract
In this study, the peptides of soy protein obtained by enzymatic digestion with pro-
teases were analyzed for their antidiabetic, antihypertensive, and antioxidant activi-
ties. Peptides prepared with alkaline proteinase (AP) exhibited the highest 
α-glucosidase inhibitory activity compared with those from papain and trypsin diges-
tion. AP hydrolysates also exhibited dipeptidyl peptidase IV (DPP‐IV) inhibitory, an-
giotensin‐converting enzyme (ACE) inhibitory, and antioxidant activities. 
Gastrointestinal digestion of peptides enhanced α‐glucosidase, DPP‐IV, and ACE in-
hibitory activities compared with AP hydrolysates. AP peptides showing highest α-
glucosidase inhibitory activity were purified by anion-exchange and size-exclusion 
chromatography， and identified using tandem MS. We found three novel α-glucosi-
dase inhibitory peptides with sequences LLPLPVLK, SWLRL, and WLRL with IC50 of 
237.43 ± 0.52, 182.05 ± 0.74, and 162.29 ± 0.74 μmol/L, respectively. Therefore, 
peptides hydrolyzed from soy protein are promising natural ingredients for nutraceu-
tical applications assisting in the management of diabetes.
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of postprandial hyperglycemia, such as α-glucosidase, α-amylase, 
and dipeptidyl peptidase IV (DPP‐IV), have been recognized as ther-
apeutic target. α-glucosidase is a membrane-bound enzyme located 
in the epithelium of the small intestine, which catalyses the cleav-
age of glucose from disaccharides (Matsui, Yoshimoto, Osajima, Oki, 
& Osajima, 1996). Inhibition of this enzyme has been recognized as 
an effective approach for lowering serum glucose level (Johnson, 
Lucius, Meyer, & Gonzalez De Mejia, 2011). α-glucosidase, which 
catalyses the reaction from dextrin to glucose in the small intestine, 
plays a key role in the digestion and absorption of carbohydrates. 
Thereby, α-glucosidase inhibitors such as acarbose, voglibose, and 
miglitol effectively diminish postprandial hyperglycemia by imped-
ing the digestion of carbohydrates. However, these types of inhib-
itors have unpleasant and potentially serious gastrointestinal side 
effects which limit use. Other therapeutic targets include dipepti-
dyl peptidase IV (DPP‐IV), which is known to cause the inactivation 
of incretin hormones GLP-1 and gastric inhibitory peptide (GIP) 
(Drucker, 2007). By inhibiting DPP‐IV, it is possible to increase the 
half-life of GLP-1 and GIP resulting in enhanced insulin secretion 
(Nongonierma & FitzGerald, 2013). Furthermore, according to the 
National Diabetes Statistic Report of USA in 2017, about 73.6% of 
adults with DM have hypertension, which increases the risk of cor-
onary heart disease (Abuissa, Jones, Marso, & O'Keefe, 2005; CDC, 
2017), peripheral artery disease, stroke, and even kidney disease. 
There is also growing evidence indicating that the development of 
diabetes is related to oxidative stress (Asmat, Abad, & Ismail, 2016). 
Therefore, it is significant for identifying diet-related strategies that 
could address these different pathologies.
Bioactive peptides have a wide range of functional properties, 
including antimicrobial, antihypertension, hypoglycemic activity, 
immunomodulation, and antioxidative functions. Due to their lower 
relative molecular weight, higher absorption, and bioavailability 
(Koopman et al., 2009), food-derived bioactive peptides have shown 
potential to serve as natural alternatives or complements to synthetic 
drugs. Many studies have demonstrated hypoglycemic effects of 
bioactive peptides from hemp seed protein, goby fish, and egg-yolk 
protein (Nasri et al., 2015; Ren et al., 2016; Zambrowicz et al., 2015).
The objective of this research was to prepare peptides from 
soy protein hydrolysates with enzymolysis and to screen bioactive 
peptides with high α-glucosidase inhibitory activities. Successive 
separation and purification were carried out, and the α-glucosidase 
inhibitory peptides were identified. We also measured the in vitro 
antioxidative activity and the angiotensin‐converting enzyme (ACE) 
inhibitory activity of the soy protein hydrolysates. The potential of 
soy bioactive peptides as ingredients for nutraceutical or functional 
food formulation is discussed.
2  | MATERIALS AND METHODS
2.1 | Materials
Soy protein powder was purchased from Harbin Gaoke Group Co., 
Ltd. Enzymes including alkaline proteinase (200 U/mg), papain 
(800 U/mg), trypsin from porcine pancreas (250 U/mg), pepsin from 
porcine gastric mucosa (500 U/mg), and pancreatin from porcine 
pancreas were purchased from the Summus Chemical Company; 
4-nitrophenyl-α-D-glucopyranoside (PNPG), α-glucosidase from 
Saccharomyces cerevisiae, acarbose hydrate; dipeptidyl peptidase IV 
(DPP‐IV) from human; gly‐pro‐p-nitroanilide, hippuryl-l-histidyl-l-
leucine (HHL), angiotensin I‐converting enzyme (ACE) from rabbit 
lung (2.0 U/mg); and hippuric acid (HA), DEAE‐52, and gel Sephadex 
G‐15 were obtained from Sigma‐Aldrich. All other chemicals and 
reagents were of analytical grade and commercially available.
2.2 | Preparation of soy protein peptides
The protein content of the raw material was determined by using 
the Kjeldahl method. Preparation of the protein hydrolysates was 
performed in a temperature- and pH-controlled 500-mL reaction 
vessel equipped with a stirrer. Three grams of soy protein powder 
was dispersed in distilled water to obtain 2% protein slurry (w/v). 
Subsequently, the protein slurry was heated to 100°C for 10 min 
for denaturation. After cooling down, 0.5 mol/L sodium hydroxide 
(NaOH) and 0.5 mol/L hydrochloric acid (HCl) aqueous solutions 
were used to adjust the pH of the slurry to the optimum conditions 
recommended by the manufacturers for each protease: AP (pH 9, 
50°C), papain (pH 6.5, 60°C), and trypsin (pH 7, 37°C). The protease 
(6,000 U/g, on the basis of the protein content of slurry) was added 
to initiate the protein enzymatic hydrolysis. Temperature and pH 
values were kept constant until the degree of hydrolysis no longer 
changed. Then, the hydrolysates were heated in a boiling water bath 
for 10 min to inactive the protease. After removal of the precipitate 
by centrifugation (4,436 g, 10 min), it was collected supernatant and 
stored at −20°C until use. The degrees of hydrolysis (DH) values were 
measured by “pH‐stat” method described by Adler‐Nissen (1986).
2.3 | Molecular weight distribution
The molecular weight distributions of hydrolysates were evalu-
ated by size-exclusion HPLC (Waters) on a TSKgel 2000 SWxl col-
umn (7.8 mm × 300 mm). One hundred milligram of hydrolysate 
powder was dissolved in 10 ml mobile phase (acetonitrile/water/
trifluoroacetic acid, 40/60/0.1), sonicated for 5 min, centrifuged at 
8,000 rpm for 10 min, and then filtered through the microporous 
membrane. The injection quantity was 10 μl with the flow rate of 
0.5 ml/min. The effluent was monitored by UV detector at 220 nm. 
Cytochrome C (MW: 12,384 Da), bacitracin (MW: 1,422 Da), leupep-
tin (MW: 427 Da), and tryptophan (MW: 204 Da) were used as mo-
lecular weight standards.
2.4 | α‐glucosidase inhibitory activity assay
α-glucosidase inhibitory activity assay was performed according to a 
method by Kim with slight modifications (Kim, Wang, & Rhee, 2004). 
The α-glucosidase inhibitory rate of the hydrolysate was estimated 
in a 96‐well microplate using a MR‐96A microplate reader (Mindray) 
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by monitoring the amount of 4-nitrophenol (PNP) released from 
4-nitrophenol-α‐D‐glucopyranoside (PNPG). A dose (50 μl) of so-
dium phosphate buffer (pH 6.8, 0.2 M), 50 μL of PNPG (1 mg/ml) 
dissolved in sodium phosphate buffer, and 50 μl of the samples dis-
solved in the same buffer were mixed adequately in a 96-well mi-
croplate. Then, it was incubated for 5 min at 37°C, and the reaction 
started immediately followed by the addition of 10 μl of α-glucosi-
dase solution (0.2 U/ml of the buffer). The plate was incubated for 
another 30 min at 37°C, and then, the reaction was terminated by 
the addition of 80 μl of 1 M Na2CO3 solution. The absorbance of re-
leased product PNP was measured immediately at 405 nm. Sodium 
phosphate buffer and acarbose (10 mg/ml of the buffer) were used 
as the negative and positive control, respectively. The percentage 
of α-glucosidase inhibition was calculated as follows:
where ODA is the absorbance of the supernatant in which the sam-
ple is replaced by the same amount of buffer; ODS is the absorbance 
of the supernatant with the tested sample; and ODB is the absorb-
ance of the supernatant in which the tested sample and α-glucosi-
dase solution are replaced by the same amount of buffer. IC50 value 
was obtained and used to evaluate the α-glucosidase inhibition rate 
of the sample, which was calculated as the concentration of the 
tested sample required for α-glucosidase inhibition rate of 50%.
2.5 | Dipeptidyl peptidase IV (DPP‐IV) 
inhibition assay
DPP‐IV inhibition assay was according to the method from Harnedy 
et al with minor modifications (Harnedy, O'Keeffe, & Fitzgerald, 
2015). The assay was performed in a 96-well microplate; 25 μl of 
test sample was preincubated with 25 μl of substrate gly-pro-p-ni-
troanilide (12 mM) at 37°C for 10 min, after added 50 μl of DPP‐IV 
(0.02 U/ml of Tris-HCl buffer, pH 8.0); the mixture was incubated at 
37°C for 30 min; and then, 100 μl acetic acid–sodium acetate (1 M) 
was added to terminate the reaction. The DPP‐IV inhibition rate (%) 
was calculated as following:
where ODA is the absorbance of the supernatant in which the tested 
sample was replaced by the same amount of buffer; ODS is the ab-
sorbance of the supernatant with the tested sample; ODB is the ab-
sorbance of the supernatant in which the tested sample and DPP‐IV 
solution are replaced by the same amount of buffer; and ODN is the 
absorbance of the supernatant in which the DPP‐IV solution is re-
placed by the same amount of buffer.
2.6 | ACE inhibition assay
The determination of ACE inhibitory activity was performed by 
using in vitro method described by Wu and Ding with slight modi-
fications (Wu & Ding, 2002). This assay was based on the release 
of HA from HHL with ACE enzymolysis. For the assay, 200 μl ACE 
(0.1 U/ml 0.1 M borate buffer containing 0.3 M NaCl at pH 8.3) 
was added to the sample (100 μl), and the mixture was incubated at 
37°C for 10 min. Then, 200 μl of HHL (5 mM in 0.1 M borate buffer 
containing 0.3 M NaCl at pH 8.3) was added into each well as sub-
strate. The enzymatic reaction subsequently carried out at 37°C for 
60 min. The reaction was terminated by adding 300 μl of 1 M HCl. 
Borate buffer was used as the control. The final HA was extracted 
with 1.5 ml of ethyl acetate; after 90°C of incubation, the organic 
layer would be dry and dissolved in 2 ml of distilled H2O. The amount 
of HA produced was determined by an HPLC system. An aliquot of 
50 μl from the reaction mixture was analyzed by an HPLC system 
equipped with Waters C18 column (ODS, 150 × 4.6 mm, 5 μm parti-
cle size) using an elution of formic acid (0.4%): methanol (3:7 v/v) at a 
constant flow rate of 0.5 ml/min, and HA was detected by UV detec-
tor at 228 nm. The ACE inhibition rate (%) was calculated as follows:
where A is the chromatography peak area of the supernatant in 
which the tested sample is replaced by the same amount of buffer; 
C is the chromatography peak area of the supernatant with tested 
sample; and B is the chromatography peak area of the supernatant 
with no tested sample and ACE solution.
2.7 | Antioxidative activities of soy protein peptides
2.7.1 | Hydroxyl radical scavenging ability
The antioxidant activity of the soy protein peptides was determined 
by a hydroxyl radical scavenging assay involving in the Fenton reac-
tion, according to Hanasaki (Hanasaki, Ogava, & Fukui, 1994). The 
samples were prepared into 0.1, 0.5, 2, 5, and 10 mg/ml. Then, 1 ml 
of 9 µmol/L FeSO4 solution and 1 ml of salicylic acid–ethanol solution 
(9 µmol/L，50% ethanol solution) were added respectively and mixed 
well, with the addition of 1 ml of 8.8 µmol/L H2O2 (0.03%) reaction 
initiated. The mixture was incubated in a 37℃ water bath for 30 min 
and then centrifuged at 2,896 g for 5 min to remove the precipitation. 
The absorbance of the supernatant was measured at 510 nm. The hy-
droxyl radical clearance rate was calculated as follows:
where A1 is the absorbance of the sample supernatant, A2 is the ab-
sorbance of the supernatant in which the salicylic acid–ethanol is 
replaced by the same amount of ethanol, and A0 is the absorbance 
of the supernatant in which the sample is replaced by distilled water. 
The ascorbic acid was used as a positive control.
2.7.2 | Ferric reducing antioxidant power 
(FRAP) activity
The FRAP assay was used to determine the antioxidative of the sam-
ples using the method described by Tsai et al with some modifications 
(1)훼−glucosidase inhibition rate (%)=
ODA−ODS
ODA−ODB
×100
(2)DPP− IV inhibition rate (%)=1−
ODS−ODN
ODA−ODB
×100
(3)ACE inhibition rate (%)=
A−C
A−B
×100
(4)Hydroxyl radical clearance rate (%)=
[
1−
A1−A2
A0
]
×100
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(Tsai, Huang, & Mau, 2006) and to configure the sample solution with 
the concentration of 1, 2, 5, 10, and 20 mg/ml. Using 1 ml of sample 
mixed with 2.5 ml of 0.2 mol/L sodium phosphate buffer (pH 6.6) 
and 2.5 ml of 1% potassium ferricyanide solution incubated at 50℃ 
for 30 min, add 2.5 ml of 10% trichloroacetic acid solution, centri-
fuged at 1,042 g for 10 min, and then collected 2.5 ml of supernatant 
mixed with 2.5 ml of distilled water and 0.5 ml of 0.1% ferric chloride 
solution. The absorbance at 700 nm was measured after 10 min by a 
754 PC spectrophotometer (Shanghai, China). FeSO4 aqueous solu-
tion was used as positive control.
2.8 | In vitro digestion simulation
According to the in vitro harmonized protocol described by Minekus 
(Minekus et al. (2014), the soy peptides were diluted to 10 mg/ml 
with deionized water and adjusted to pH 2.0 with 1 M HCL. Then, 
hydrolysis was started by adding the pepsin (2.5 U/mg substrate) 
from porcine gastric mucosa, the mixture was incubated for 2 hr at 
37°C in a water bath with stirring, and pH value was adjusted to 7.2 
with 1 M NaOH solution. To simulate the digestion of small intestine, 
pancreatin (E: S = 4:100) from porcine pancreas was added in the 
mixture to start the hydrolysis sequentially. The mixture was incu-
bated at 37°C for 2 hr, and the pH value was kept to 7.2 with 1 M 
NaOH. After the incubation, the digestion process was terminated 
after enzyme denaturation through increasing the temperature to 
95°C for 20 min. The soy peptides were separated from the reaction 
mixtures after digestion by centrifugation at 8,000 rpm for 10 min. 
The inhibitory activities of ACE, α‐glucosidase, and DPP‐IV of the 
supernatants were determined by the methods mentioned above.
2.9 | Isolation of α‐glucosidase inhibitory peptides 
from soy protein hydrolysate
2.9.1 | Ion‐exchange resin (DEAE‐52)
The soy protein hydrolysate showing highest α-glucosidase inhibi-
tion activity was first fractionated by using anion-exchange chro-
matography DEAE‐52. The freeze‐dried hydrolysate was dissolved 
in distilled water to the concentration of 20 mg/ml. Then, 4 ml of 
hydrolysate was loaded into the DEAE‐52 anion‐exchange column 
(6 mm × 30 cm, Qingdao Bishui Hantian Biological Co., Ltd.) pre-
equilibrated with the starting buffer (Tris-HCl, pH = 8). The adsorbed 
peptides were eluted as the concentrations of NaCl increased (0, 
0.05, 0.1, 0.2, 0.3 M) in the starting buffer with a flow rate of 1.5 ml/
min for 6 hr. The elution peaks were monitored at 220 nm, and the 
fractions were collected every 5 min. Factions eluted within each 
peak were pooled together, desalted with dialysis bag (200 Da cut-
off), and assessed for their α-glucosidase inhibitory activities. The 
separation process was repeated for gathering enough to further 
purification. Then, the sample was concentrated by rotary evapora-
tion and purified by the size-exclusion chromatography for further 
analysis.
2.9.2 | Gel filtration chromatography (G‐15)
Three microliters of fraction from ion-exchange chromatog-
raphy (10 mg/ml) was loaded into a chromatography column 
(6 mm × 60 cm) packed with the pretreated gel Sephadex G-15 
(Beijing Solarbio Science & Technology Co., Ltd.). Then, the sample 
eluted using distilled water with the flow rate of 0.5 ml/min. The 
peptide elution was monitored by measurement of the absorbance 
at 220 nm, and fractions were collected. Separation process was 
repeated multiple times, and the α-glucosidase inhibitory activi-
ties of collected fractions were analyzed. The fraction with the α-
glucosidase inhibitory activity marked by H1-1 was concentrated 
by rotary evaporation and subjected to the subsequent analysis 
and identification procedure.
2.10 | Identification of peptide sequence (LC‐MS/
MS)
The amino acid sequence and the molecular mass of H1-2 were 
analyzed by (Qingdao Sci-tech innovation Co., Ltd.) with online 
nanospray LC‐MS/MS on a Q Exactive Plus coupled to an EASY‐
nano-LC 1200 system (Thermo Fisher Scientific). Five microliters 
of the sample was loaded into the trap column (Thermo Fisher 
Scientific Acclaim PepMap C18, 100 μm × 2 cm), with a flow 
rate of 10 μL/min, and subsequently separated on the analyti-
cal column (Acclaim PepMap C18, 75 μm × 15 cm), with a linear 
gradient, from 3% to 38% B (A: distilled water, B: 0.1% formic 
acid in ACN) in 60 min. The column flow rate was maintained at 
0.5 ml/min with the column temperature of 40°C. The peptide 
sequences of the major peaks were performed by processing the 
ion series in MS/MS spectra using Peaks Studio 8.5 and manual 
interpretation.
A spray voltage of 2 kV was applied, and the instrument, Q 
Exactive Plus, was operated under switching automatically between 
MS full scan and data-dependent fragmentation modes with 27 of 
collision energy. Ions were scanned at high resolution (70,000 in 
MS1, 17,500 in MS2), and the MS scan range was 100–1500 m/z at 
both MS1 and MS2 levels.
2.11 | Peptide synthesis
Synthetic peptides were provided by Qingdao China Peptides Co., 
Ltd. using the conventional Fmoc solid-phase synthesis method. 
Synthetic peptides were purified and determined by HPLC-MS anal-
ysis with the purification rate over than 98%.
2.12 | Statistical analysis
The data were expressed as the mean of three replicates and stand-
ard deviation (SD). Statistical calculation was performed by ANOVA 
with IBM SPSS statistics, version 25 (IBM Inc.). Differences were 
considered to be significant at p < 0.05.
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3  | RESULTS AND DISCUSSION
3.1 | Preparation of peptides with α‐glucosidase 
inhibitory activity
To prepare the antidiabetic bioactive peptides, soy protein iso-
late (protein content 86.62%) was hydrolyzed with AP, papain, and 
trypsin, respectively, and α-glucosidase inhibitory activity of hydro-
lysates was analyzed.
As shown in Figure 1, the peptides released by three proteases 
displayed different hydrolytic processes and different α-glucosidase 
inhibitory activities. During all three enzymolysis processes, the DH 
of hydrolysates increased with hydrolysis time, and the DH of hy-
drolysates released by papain and trypsin reached 5.92 ± 1.31% and 
8.10 ± 0.82%, respectively. The highest DH value of hydrolysates 
was 36.84 ± 1.20%, which was obtained by AP after 8‐hr hydrolysis 
time. This result was similar to the study on soy protein hydroly-
sates by Hrckova et al., and they obtained 35.1% of DH value after 
8‐hr hydrolysis time with AP (Hrckova, Rusnakova, & Zemanovic, 
2002). It was supposed that different cleavage sites of the three 
proteases result in the difference of DH value during the hydrolytic 
processes. AP is an endoenzyme with a broad specificity, which 
preferentially cleaves peptide bonds on the C-terminal of hydro-
phobic amino acid residues, such as Typ, Phe, Leu, Ile, Val, and Met, 
and higher DH value can be achieved with longer enzymolysis time 
(Nourmohammadi, SadeghiMahoonak, Alami, & Ghorbani, 2017). 
While trypsin cleaves solely C‐terminal to Arg and Lys, papain pre-
fers to cleave the peptides bonds between the carboxylic acid group 
of Lys or Arg and adjacent amino acid residue. The highest α-gluco-
sidase inhibition rate (53.79 ± 3.24%) of the hydrolysate released 
by AP was derived at the DH value of 36.84 ± 1.20%. Figure 1 also 
shows that the DH value positively affected the inhibition rates of 
the hydrolysates.
Table 1 shows the results of the molecular weight distribution. 
There were 95.39% of the hydrolysates with molecular weight lower 
than 2,000 Da and 69.76% with molecular weight lower than 500 Da.
3.2 | Inhibitory activities of soy protein peptides 
against α‐glucosidase and DPP‐IV
The soy protein peptides obtained by AP hydrolysis were freeze‐
dried after the removal of insoluble precipitation. Inhibitory activi-
ties against α‐glucosidase and DPP‐IV of soy protein peptides were 
measured. α-Glucosidase is a membrane-bound enzyme located in 
the epithelium of the small intestine that catalyses the cleavage of 
glucose from disaccharides (Matsui et al., 1996). Inhibition of this 
enzyme has been recognized as an effective approach to reduce 
the serum glucose level (Johnson et al., 2011). Since hydrolysates 
are crude mixtures of proteins, the α-glucosidase inhibitory activ-
ity of acarbose (IC50 = 0.52 ± 0.05 mg/ml) was higher than the hy-
drolysates that the IC50 of α-glucosidase inhibitory activity was 
4.94 ± 0.07 mg/ml.
DPP‐IV is known for its inactivation of incretin hormones GLP‐1 
and GIP (Drucker, 2007). By inhibiting DPP‐IV, it is possible to in-
crease the half-life of GLP-1 and GIP resulting in enhanced insulin 
secretion (Nongonierma & FitzGerald, 2013). The same prepara-
tion had high DPP‐IV inhibition activity with the IC50 value of 
2.73 ± 0.08 mg/ml.
The soy peptides we screened contained small peptides with a 
molecular weight between 180 and 500 Da, that is, about 2–5 amino 
acids.
3.3 | Antioxidation and ACE inhibition activities of 
soy protein hydrolysates
Since oxidative stress also affects the development of diabetes, 
the antioxidative activities of hydrolysate were evaluated. The soy 
hydrolysates obtained by AP exhibited hydroxyl radical scavenging 
ability (IC50 = 5.30 ± 0.15 mg/ml), while it was weaker than that of 
vitamin C (IC50 = 0.54 ± 0.04 mg/ml). As shown in Figure 2, iron ion 
reduction ability of both hydrolysates and FeSO4 solution was line-
arly related to concentration, and at the same concentration, ferrous 
sulfate possessed stronger reduction ability.
Renin–angiotensin system is an important regulator of blood 
pressure and vascular distention, and the ACE plays a key role by 
hydrolyzing angiotensin I to angiotensin II, which possesses strong 
F I G U R E  1   α-glucosidase inhibition rates (solid symbols) and 
DH values (open symbols) of hydrolysates prepared with AP ( ♢，♦), 
papain ( △, ▲), and trypsin (○,●)
TA B L E  1   Molecular weight distribution of soy protein peptides 
generated by AP enzymolysis
Molecular 
weight range 
(Da)
Peak 
molecular 
weight
Retention 
time (min)
Distribution of 
Mw classes (%)
>5,000 6,764 12.512 1.16
5,000–3,000 3,393 13.851 1.68
3,000–2,000 2019 14.859 2.10
2,000–1,000 1,000 16.223 6.60
1,000–500 500 17.568 18.70
500–180 233 19.049 53.53
<180 179 19.563 16.23
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vasoconstrictor effect. The soy protein hydrolysate produced by 
AP inhibited 20.31 ± 2.37% of ACE that was in accordance with the 
study performed by Wu and Ding (2002). Therefore, soy protein hy-
drolysates showed the potential to be a multifunction nutraceutical 
agent. The structure of the peptides may be closely related to ACE 
inhibitory effects. It is reported that the position of a hydrophobic 
amino acid at the C‐terminal end is associated with ACE inhibitory 
activity (Escudero, Toldra, Sentandreu, Nishimura, & Arihara, 2012). 
Soy protein belongs to plant protein and contains more hydrophobic 
amino acids (Zhang et al., 2017).
3.4 | Simulated gastrointestinal digestion
Before and after in vitro simulated digestion, the inhibitory activi-
ties against α‐glucosidase, DPP‐IV, and ACE of soy protein peptides 
were measured, and the results are shown in Figure 3. Before di-
gestion, soy peptides with a concentration of 10.0 mg/ml indicated 
that the inhibition rate was 29.04 ± 1.49%, 40.85 ± 0.82%, and 
20.31 ± 2.37% against α‐glucosidase, DPP‐IV, and ACE, respectively. 
After gastric phase digestion, α-glucosidase inhibitory activity of the 
peptides significantly increased up to 75.53 ± 1.44% (p < 0.05), and 
after intestinal digestion, it reached to 77.64 ± 1.07%. For inhibitory 
activities against DPP‐IV, compared with undigested soy peptides, 
we also observed significant change (p < 0.05) after gastric and 
intestinal digestion, and it was 44.51 ± 0.95% and 47.94 ± 1.10%, 
respectively. For ACE inhibition activity, we found that after gas-
tric digestion, it increased slightly to 21.71 ± 1.52% (p > 0.05), and 
after intestinal digestion, the inhibition rate enhanced significantly 
to 51.43 ± 1.74% (p < 0.05). Akillioglu and Karakaya reported an in-
crease of ACE inhibitory activity in legume hydrolysates after the 
gastrointestinal digestion (Akıllıoğlu & Karakaya, 2009). Conversely, 
Tavares et al found that a slight decrease in ACE inhibitory activity of 
F I G U R E  2   Ferric reducing antioxidant power with different 
concentrations of peptides solution (○) and FeSO4 solution (□)
F I G U R E  3   Inhibitory activities of peptides against α-
glucosidase, DPP‐IV, and ACE during the digestion process
F I G U R E  4   α-glucosidase inhibitory activities of fractions H1, H2, 
H3, and H4. Inset: Elution profile of hydrolysates with DEAE‐52
F I G U R E  5   α-glucosidase inhibitory activities of fractions H1-1, 
H1-2. Inset: Elution profile of H1 with Sephadex G15
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peptides from whey protein after the digestion (Tavares et al., 2011). 
Although we do not know the reasons leading to different results, 
the amino acid sequence of peptides and inhibitory mechanism of 
peptides against ACE should be considered.
In general, this result demonstrated that the peptides could en-
dure the whole digestive environment and still maintain or enhance 
their bioactivity.
3.5 | Separation and purification
In order to purify peptides with α-glucosidase inhibitory activ-
ity, successive chromatographic separations were performed with 
anion‐exchange resin DEAE‐52 and Sephadex‐15 gel. As shown in 
Figure 4 (inset), four fractions (H1, H2, H3, and H4) were obtained 
after gradient elution through DEAE‐52. α-glucosidase inhibition 
F I G U R E  6   Identification of the peptides by EASY‐MS/MS. (a) HPLC chromatography of peptides; (b) LLPLPVLK; (c) WLRL; (d) SWLRL; (e) 
MLPVMR
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rates of each fraction were determined, and the results were shown 
in Figure 4. After the H1 was washed off by distilled water, it was 
found that H1 was only the effective inhibitor on the α-glucosidase 
with inhibition rate 87.10 ± 2.70%, and the inhibitory activity was 
higher than the original hydrolysates. All other fractions were not 
able to inhibit α-glucosidase.
We collected and concentrated H1 fraction by rotary evapora-
tion, then purified further by size‐exclusion chromatography. As 
shown in Figure 5 inset, fractionation by size of the H1 fraction re-
vealed a relatively clear molecular weight distribution profiles with 
only two main peaks (H1-1, H1-2). Figure 5 illustrates these two frac-
tions both had α-glucosidase inhibition activity, and H1-2 showed high 
α-glucosidase inhibition activity up to 95.35 ± 2.70% inhibitory rate, 
which was much higher than H1-1 with 26.08 ± 2.12% inhibitory rate.
3.6 | Identification of purified peptides
We determined molecular weight of the purified fraction H1-2 
with EASY‐MS. The results showed four abundant ions with 
m/z of 893.6, 588.4, 675.4, and 745.4, which revealed four oli-
gopeptides that would be further sequenced using LC-MS/MS. 
We obtained the complete amino acid sequences by amino acid 
composition analysis and manual calculation of the MS/MS spec-
trum. As shown in Figure 6, the first octapeptide was identified as 
LLPLPVLK, while the second peptide consisted of four amino acids 
with the sequence of WLRL. Besides, peptides with five amino 
acid SWLRL and hexapeptide MLPVMR were also identified. 
Compared with the previously reported hypoglycemic peptides, 
such as N159-1 (PFP separated from Aspergillus oryzae) (Kang, Yi, 
& Lee, 2013), albumin (KLPGF) (Yu, Yin, Zhao, Liu, & Chen, 2012), 
and egg white protein (RVPSLM) (Yu et al., 2011), there appear 
to be no primary structural homology to the four oligopeptides 
we found. It is not difficult to point out that hydrophobic amino 
acids were common in these hypoglycemic peptides. In particular, 
Leu and Pro showed outstanding contributions to these oligopep-
tides separated from soy protein (Sadri, Larki, & Kolahian, 2017). 
It was reported that Pro and Leu in peptides were considered as 
vital amino acids playing inhibition effect against α-glucosidase 
separately or synergistically, which should be taken into account 
in the synthesis of novel α-glucosidase inhibitory peptides for an-
tidiabetic treatment.
3.7 | Antidiabetic properties of synthetic peptides
The synthesized peptides have been confirmed the great inhibi-
tory effect on α‐glucosidase activity. The hexapeptides, MLPVMR, 
did not show inhibitory activity. However, other three peptides, 
LLPLPVLK, SWLRL, and WLRL, had great inhibitory influence on 
α-glucosidase with the IC50 value of 237.43 ± 0.52, 182.05 ± 0.74, 
and 165.29 ± 0.74 μmol/L. It has been suggested that the inhibi-
tory mechanism could be through the hydrophobic interactions of 
the polypeptide with the active site of the enzyme, as it has been 
reported for other inhibitors (Bharatham, Bharatham, Park, & Lee, 
2008). The peptides we found are rich in hydrophobic amino acids, 
especially the Leu, which might play an important role to inhibit 
α-glucosidase.
4  | CONCLUSIONS
In summary, the peptides possessing high α-glucosidase inhibitory 
effect were successfully prepared from soy protein treated via 
an AP process at the DH value of 36.84 ± 1.20% in the present 
study. The soy protein peptides also exhibited antioxidative activ-
ity and inhibition activities against DPP‐IV and ACE. The peptides 
with α-glucosidase inhibition activity were separated with anion-
exchange resin, Sephadex G-15 gel, which was determined using 
LC-MS/MS sequentially. The IC50 α-glucosidase inhibitory activ-
ity values of LLPLPVLK， SWLRL, and WLRL were 237.43 ± 0.52, 
182.05 ± 0.74, and 165.29 ± 0.74 μmol/L, respectively. Compared 
with other α-glucosidase inhibitory peptides, these three peptides 
we found showed different structural homology from them, as 
well as lower IC50 value than acarbose. Therefore, this research 
can be referenced for the development of novel antidiabetic pep-
tide nutraceuticals. Also, in order to validate the findings of the 
present study, further research in cell culture and in vivo should 
be needed.
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